Flavia M. Facio

Flavia M. Facio

Auto-generated profile, based on publicly available information

Flavia M. Facio

GeneDx LLC, Gaithersburg, MD, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2023 in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Verified
Journal Article
Open access
SASwaroop Aradhya
Swaroop Aradhya
FFFlavia M. Facio
Flavia M. Facio
HMHillery Metz
Hillery Metz
TMToby Manders
Toby Manders
ACAlexandre Colavin
Alexandre Colavin
RNRobert L. Nussbaum
Robert L. Nussbaum
The transition from analog to digital technologies in clinical laboratory genomics is ushering in an era of “big data” in ways that will exceed human capacity to rapidly and reproducibly analyze those data using conventional approaches. Accurately evaluating complex molecular data to facilitate timely diagnosis and management of genomic disorders will require supportive artificial intelligence methods. These are already being introduced into clinical laboratory genomics to identify variants in DNA sequencing data, predict the effects of DNA variants on protein structure and function to inform clinical interpretation of pathogenicity, link phenotype ontologies to genetic variants identified through exome or genome sequencing to help clinicians reach diagnostic answers faster, correlate genomic data with tumor staging and treatment approaches, utilize natural language processing to identify critical published medical literature during analysis of genomic data, and use interactive chatbots to identify individuals who qualify for genetic testing or to provide pre‐test and post‐test education. With careful and ethical development and validation of artificial intelligence for clinical laboratory genomics, these advances are expected to significantly enhance the abilities of geneticists to translate complex data into clearly synthesized information for clinicians to use in managing the care of their patients at scale.

15 October 2021 in Human Genetics
Verified
Journal Article
Open access
PDF file
MWMary C Whitman
Mary C Whitman
BBBrenda J. Barry
Brenda J. Barry
CRCaroline Robson
Caroline Robson
FFFlavia M. Facio
Flavia M. Facio
CRCarol Van Ryzin
Carol Van Ryzin
EEElizabeth C Engle
Elizabeth C Engle
Microtubules are formed from heterodimers of alpha- and beta-tubulin, each of which has multiple isoforms encoded by separate genes. Pathogenic missense variants in multiple different tubulin isoforms cause brain malformations. Missense mutations in TUBB3, which encodes the neuron-specific beta-tubulin isotype, can cause congenital fibrosis of the extraocular muscles type 3 (CFEOM3) and/or malformations of cortical development, with distinct genotype–phenotype correlations. Here, we report fourteen individuals from thirteen unrelated families, each of whom harbors the identical NM_006086.4 (TUBB3):c.785G>A (p.Arg262His) variant resulting in a phenotype we refer to as the TUBB3 R262H syndrome. The affected individuals present at birth with ptosis, ophthalmoplegia, exotropia, facial weakness, facial dysmorphisms, and, in most cases, distal congenital joint contractures, and subsequently develop intellectual disabilities, gait disorders with proximal joint contractures, Kallmann syndrome (hypogonadotropic hypogonadism and anosmia), and a progressive peripheral neuropathy during the first decade of life. Subsets may also have vocal cord paralysis, auditory dysfunction, cyclic vomiting, and/or tachycardia at rest. All fourteen subjects share a recognizable set of brain malformations, including hypoplasia of the corpus callosum and anterior commissure, basal ganglia malformations, absent olfactory bulbs and sulci, and subtle cerebellar malformations. While similar, individuals with the TUBB3 R262H syndrome can be distinguished from individuals with the TUBB3 E410K syndrome by the presence of congenital and acquired joint contractures, an earlier onset peripheral neuropathy, impaired gait, and basal ganglia malformations.

6 July 2006 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
JJJennifer Johnston
Jennifer Johnston
RWRobert L Walker
Robert L Walker
SDSean Davis
Sean Davis
FFFlavia Facio
Flavia Facio
JTJoyce T Turner
Joyce T Turner
LBLeslie G Biesecker
Leslie G Biesecker
Contiguous gene syndromes cause disorders via haploinsufficiency for adjacent genes. Some contiguous gene syndromes (CGS) have stereotypical breakpoints, but others have variable breakpoints. In CGS that have variable breakpoints, the extent of the deletions may be correlated with severity. The Greig cephalopolysyndactyly contiguous gene syndrome (GCPS-CGS) is a multiple malformation syndrome caused by haploinsufficiency of GLI3 and adjacent genes. In addition, non-CGS GCPS can be caused by deletions or duplications in GLI3. Although fluorescence in situ hybridisation (FISH) can identify large deletion mutations in patients with GCPS or GCPS-CGS, it is not practical for identification of small intragenic deletions or insertions, and it is difficult to accurately characterise the extent of the large deletions using this technique. We have designed a custom comparative genomic hybridisation (CGH) array that allows identification of deletions and duplications at kilobase resolution in the vicinity of GLI3. The array averages one probe every 730 bp for a total of about 14 000 probes over 10 Mb. We have analysed 16 individuals with known or suspected deletions or duplications. In 15 of 16 individuals (14 deletions and 1 duplication), the array confirmed the prior results. In the remaining patient, the normal CGH array result was correct, and the prior assessment was a false positive quantitative polymerase chain reaction result. We conclude that high-density CGH array analysis is more sensitive than FISH analysis for detecting deletions and provides clinically useful results on the extent of the deletion. We suggest that high-density CGH array analysis should replace FISH analysis for assessment of deletions and duplications in patients with contiguous gene syndromes caused by variable deletions.

16 February 2026 in Human Genetics
Verified
Journal Article
Open access
PDF file
VUVincent D Ustach
Vincent D Ustach
MSMaria J. Guillen Sacoto
Maria J. Guillen Sacoto
SMStephen McGee
Stephen McGee
VGVladimir G. Gainullin
Vladimir G. Gainullin
KAKevin Arvai
Kevin Arvai
TLTimothy Laurent
Timothy Laurent
A challenge for clinical exome and genome sequencing (ES/GS) analysis is correlating the clinical presentation of the cases being tested with known gene-phenotype associations (GPAs). We developed Multiscore, a gene prioritization tool, to facilitate gene-level predictions of phenotypic fit. Multiscore combines data inputs and algorithms to generate similarity subscores that feed a random forest (RF) classifier trained to predict the probability of association between the patient’s clinical features and the gene. The reference GPAs are extracted from: (1) OMIM, (2) patient descriptions in the literature, and (3) GeneDx (GDx) clinical data. We used 9,989 ES/GS cases to assess performance of the tool in combination with genotype filtering. Genotype filters rendered an average of 173 genes with variants requiring clinical review. Multiscore prioritized the reported positive gene with a median rank of 3 and mean rank of 6.35. The average recall (sensitivity) of Multiscore was 33% in the top 1, 69% in the top 5, 83% in the top 10, and 93% in the top 20 ranked genes. Multiscore was able to handle non-exact HPO term matches allowing the use of real-world clinical data. 74 genes lacking OMIM entries were prioritized using only the GDx and literature datasets. Multiscore allows the phenotype review to prioritize the most relevant genes, increasing case throughput and broadening access to diagnoses for patients.

1 August 2025 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
CNChai-Ann Ng
Chai-Ann Ng
MOMatthew J. O’nEill
Matthew J. O’nEill
SPSamskruthi R. Padigepati
Samskruthi R. Padigepati
YTYi-Lee Ting
Yi-Lee Ting
FFFlavia M. Facio
Flavia M. Facio
BKBrett M. Kroncke
Brett M. Kroncke

8 February 2025 in medRxiv
Verified
Preprint
Open access
PDF file
CNChai-Ann Ng
Chai-Ann Ng
MOMatthew J. O’neill
Matthew J. O’neill
SPSamskruthi R. Padigepati
Samskruthi R. Padigepati
YTYi-Lee Ting
Yi-Lee Ting
FFFlavia M. Facio
Flavia M. Facio
BKBrett M. Kroncke
Brett M. Kroncke
Rare missense variants are often classified as variants of uncertain significance (VUS) due to insufficient evidence for classification. These ambiguous findings create anxiety and frequently lead to inappropriate workup, colloquially referred to as the ‘diagnostic odyssey’. Well-validated high-throughput experimental data have the potential to significantly reduce the number of VUS identified by clinical genetic testing, though the extent of this reduction and the optimal strategies to achieve it remain unclear. 1